Pure Biologics S.A. (WSE:PUR)

Poland flag Poland · Delayed Price · Currency is PLN
2.580
-0.095 (-3.55%)
Apr 28, 2026, 5:00 PM CET
-71.80%
Market Cap 31.59M
Revenue (ttm) n/a
Net Income (ttm) -17.93M
Shares Out 12.24M
EPS (ttm) -4.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 99,511
Average Volume 608,160
Open 2.700
Previous Close 2.675
Day's Range 2.525 - 2.720
52-Week Range 1.353 - 10.060
Beta 0.47
RSI 48.37
Earnings Date Apr 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wrocław, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange Warsaw Stock Exchange
Ticker Symbol PUR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.